87 reports

Global Genetic Disorders Partnering 2014-2020: Deal trends, players and financials Executive Summary Chapter ## – Introduction Chapter ## – Trends in Genetic Disorders dealmaking ##. ##.

  • Genetic Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • Demand
  • GENETIC DISORDERS, COMMON SYMPTOMS OF GENETIC DISORDERS
  • TO GENETIC DISORDERS, 2016-2023

Most genetic disorders are quite rare and affect one person in several thousand or even millions.

  • Genetic Disorder
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.

Ten-year test volume and reagent sales forecasts for the following categories: & nbsp; & nbsp; & nbsp; - & nbsp; Infectious Diseases Genetic Diseases & nbsp; & nbsp; & nbsp; - & nbsp; Cancer & nbsp; & nbsp; & nbsp; - & nbsp; Paternity Testing/

  • Genetic Disorder
  • Pathology
  • Spain
  • Forecast

Ten-year test volume and reagent sales forecasts for the following categories: & nbsp; & nbsp; & nbsp; - & nbsp; Infectious Diseases Genetic Diseases & nbsp; & nbsp; & nbsp; - & nbsp; Cancer & nbsp; & nbsp; & nbsp; - & nbsp; Paternity Testing/

  • Genetic Disorder
  • Pathology
  • Spain
  • Demand

Ten-year test volume and reagent sales forecasts for the following categories: & nbsp; & nbsp; & nbsp; - & nbsp; Infectious Diseases Genetic Diseases & nbsp; & nbsp; & nbsp; - & nbsp; Cancer & nbsp; & nbsp; & nbsp; - & nbsp; Paternity Testing/

  • Genetic Disorder
  • Pathology
  • Spain
  • Demand
  • Forecast

Ten-year test volume and reagent sales forecasts for the following categories: & nbsp; & nbsp; & nbsp; - & nbsp; Infectious Diseases Genetic Diseases & nbsp; & nbsp; & nbsp; - & nbsp; Cancer & nbsp; & nbsp; & nbsp; - & nbsp; Paternity Testing/

  • Genetic Disorder
  • Pathology
  • Spain
  • Demand

Ten-year test volume and reagent sales forecasts for the following categories: & nbsp; & nbsp; & nbsp; - & nbsp; Infectious Diseases Genetic Diseases & nbsp; & nbsp; & nbsp; - & nbsp; Cancer & nbsp; & nbsp; & nbsp; - & nbsp; Paternity Testing/

  • Genetic Disorder
  • Pathology
  • Spain
  • Demand
  • Genetic diseases
  • Non-genetic diseases

The following are the commonly occurring monogenic disorders: Common types of genetic disorders Genetic diseases Global prenatal DNA sequencing market by genetic diseases - Market size and forecast 2017-2022 ($ mn) Down syndrome is one o

  • Genetic Disorder
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Natera, Inc.
  • Growing Prevalence Of Genetic Diseases
  • Increasing Research On Genetic Diseases

Genetic diseases are one of the leading cause of infant death in the US.

  • Genetic Disorder
  • World
  • Forecast
  • Market Size
  • PerkinElmer, Inc.

Rare diseases are often the result of a genetic mutation; one estimate is that ##% of rare diseases are genetic in nature.

  • Genetic Disorder
  • Forecast
  • Exact Sciences Corp.
  • Illumina, Inc.
  • LabCorp Specialty Testing Group

Cystic fibrosis (CF) is a rare and progressive genetic disorder that is characterized by an abnormal movement of sodium and chloride across the gastrointestinal and respiratory tracts.

  • Genetic Disorder
  • World
  • Demand
  • Forecast
  • Market Size
  • JAPAN - CYSTIC FIBROSIS THERAPEUTICS MARKET (MILLION US$), 2014 - 2016
  • 6.2 CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET & FORECAST

Cystic fibrosis is a hereditary genetic disease afflicting about one in ## newborns in the US and Europe.

  • Genetic Disorder
  • World
  • Market Size
  • AbbVie Inc.
  • Editas Medicine, Inc.
  • II. Etiology and Genetics of Cystic Fibrosis
  • 1. CYSTIC FIBROSIS: DISEASE OVERVIEW

Etiology and Genetics of Cystic Fibrosis Cystic Fibrosis is a genetic disorder caused by having two mutated copies of the CFTR gene, each one copy from both parents. b.

  • Cystic Fibrosis
  • Genetic Disorder
  • World
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated

DISEASE DEFINITION AND DIAGNOSIS ## PATIENT SEGMENTATION ## CURRENT TREATMENT OPTIONS ## PRESCRIBING TRENDS ## UNMET NEEDS IN CYSTIC FIBROSIS ## EPIDEMIOLOGY: CYSTIC FIBROSIS (Published on ## September 2018) ## OVERVIEW ## DISEASE BACKGROUND ## METHODOLOGY ## FORE

  • Cystic Fibrosis
  • Genetic Disorder
  • Pathology
  • European Union
  • United States

GENETIC FACTORS ARE ALSO A CONTRIBUTOR TO IPF; AROUND ## IN ## PEOPLE WITH IPF HAVE ANOTHER FAMILY MEMBER WITH THE DISEASE DUE TO A DISEASE CALLED FAMILIAL IDIOPATHIC FIBROSIS.

  • Genetic Disorder
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biologics, Inc.
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF POLYCYSTIC KIDNEY DISEASE TO GENETIC DISORDERS CLINICAL TRIALS
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF POLYCYSTIC KIDNEY DISEASE TO GENETIC DISORDERS CLINICAL TRIALS

PROPORTION OF POLYCYSTIC KIDNEY DISEASE TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2020* PROPORTION OF POLYCYSTIC KIDNEY DISEASE TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2020* In total there were ## clinical trials co

  • Genetic Disorder
  • Pharmaceutical
  • World
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.
  • GENE THERAPY TO ACTIVATE GLUCOCEREBROSIDASE FOR GENETIC DISORDERS - DRUG PROFILE
  • GAUCHER DISEASE - PIPELINE BY BLUE TURTLE BIO TECHNOLOGIES INC, H1 2020

It offers titratable, re-dosable genetic medicines with drug-like properties to patients suffering with genetic diseases.

  • Genetic Disorder
  • Therapy
  • United States
  • Product Initiative
  • Genzyme Corporation
  • PROPORTION OF DOWN SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2019*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF DOWN SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS

PROPORTION OF DOWN SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2019* PROPORTION OF DOWN SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2019* In total there were ## clinical trials conducted on Down Syndrome, as of May 2019 in

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • F. Hoffmann-La Roche Ltd.

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Canada
  • France
  • Italy
  • Forecast
  • PROPORTION OF DUCHENNE MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2019*
  • PROPORTION OF DUCHENNE MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2019*

The genetic disorder' s symptoms include cell damage, impaired calcium homeostasis, increased oxidative stress and reduced energy production in muscle cells.

  • Drug Development
  • Genetic Disorder
  • Pharmaceutical
  • World
  • Product Initiative
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF CYSTINOSIS TO GENETIC DISORDERS CLINICAL TRIALS
  • PROPORTION OF CYSTINOSIS TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2019*

PROPORTION OF CYSTINOSIS TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2019* PROPORTION OF CYSTINOSIS TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2019* PROPORTION OF CYSTINOSIS TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTR

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Horizon Pharma plc
  • 7.3 GENETIC DISORDERS
  • VIRAL VECTOR MANUFACTURING MARKET FOR GENETIC DISORDERS, BY REGION, 2016-2023 (USD MILLION)

More than ## potential gene therapies for cancers, genetic disorders, and infectious diseases are currently under development.

  • Genetic Disorder
  • Pharmaceutical
  • North America
  • United States
  • Market Size
  • PROPORTION OF BECKER MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF BECKER MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF BECKER MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF BECKER MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* IN TOTAL THERE WERE ## CLINICAL TRIALS CONDUCTED ON BECKER M

  • Genetic Disorder
  • Neurological Disorder
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF TURNER SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF TURNER SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*

PROPORTION OF TURNER SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF TURNER SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* TURNER SYNDROME THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* In t

  • Genetic Disorder
  • Human Growth Hormone
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* IN TOTAL THERE WERE ## CLINICAL TRIALS CONDUCTED ON

  • Antiviral
  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF CHEDIAK-HIGASHI SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF CHEDIAK-HIGASHI SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF CHEDIAK-HIGASHI SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF CHEDIAK-HIGASHI SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* IN TOTAL THERE WERE ## CLINICAL TRIALS CONDUCTED ON CHEDIAK-HI

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Miltenyi Biotec GmbH
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF TUBEROUS SCLEROSIS TO GENETIC DISORDERS CLINICAL TRIALS
  • PROPORTION OF TUBEROUS SCLEROSIS TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2018*

TUBEROUS SCLEROSIS THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY TRIAL STATUS, 2018* CLINICAL TRIALS BY E## COUNTRIES: PROPORTION OF TUBEROUS SCLEROSIS TO GENETIC DISORDERS CLINICAL TRIALS Among the E## (Brazil, Russia, India, China, Mexico, Turkey and Indonesia) countries, China ha

  • Genetic Disorder
  • Neurological Disorder
  • World
  • Product Initiative
  • Novartis AG
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF ADRENOLEUKODYSTROPHY (ADRENOMYELONEUROPATHY/ SCHILDER-ADDISON COMPLEX) TO GENETIC DISORDERS CLINICAL TRIALS
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF ADRENOLEUKODYSTROPHY (ADRENOMYELONEUROPATHY/ SCHILDER-ADDISON COMPLEX) TO GENETIC DISORDERS CLINICAL TRIALS

PROPORTION OF ADRENOLEUKODYSTROPHY (ADRENOMYELONEUROPATHY/ SCHILDER-ADDISON COMPLEX) TO GENETIC DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF ADRENOLEUKODYSTROPHY (ADRENOMYELONEUROPATHY/ SCHILDER-ADDISON COMPLEX) TO GENETIC DISORDERS C

  • Clinical Trial
  • Dementia
  • Genetic Disorder
  • World
  • Product Initiative
  • PROPORTION OF UREA CYCLE DISORDERS TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF UREA CYCLE DISORDERS TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

PROPORTION OF UREA CYCLE DISORDERS TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF UREA CYCLE DISORDERS TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* In total there were ## clinical trials conducted on Urea Cycle Disorde

  • Clinical Trial
  • Genetic Disorder
  • World
  • Product Initiative
  • Horizon Pharma plc
  • PROPORTION OF ALPHA-MANNOSIDOSIS TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF ALPHA-MANNOSIDOSIS TO GENETIC DISORDERS CLINICAL TRIALS

PROPORTION OF ALPHA-MANNOSIDOSIS TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* PROPORTION OF ALPHA-MANNOSIDOSIS TO GENETIC DISORDERS CLINICAL TRIALS, G## COUNTRIES (%), 2018* In total there were ## clinical trials conducted on Alpha-Mannosidosis, as

  • Clinical Trial
  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative